Results 51 to 60 of about 12,098 (189)

Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression

Thoracic Cancer, 2023
Background The vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients treated with ROS1
Tara L. Peters, Nan Chen, Logan C. Tyler, Anh T. Le, Anastasios Dimou, Robert C. Doebele   +5 more
doaj   +1 more source

Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene [PDF]

, 2017
Timeline. This file shows timeline of both described cases.
Anna Seehofnerova, Elleni Michu, Jakub Neradil, Jana Soukalova, Jaroslav Sterba, Kristyna Melicharkova, Marta Jezova, Ondrej Rohleder, Ondrej Slaby, Peter Mudry, Renata Veselska   +10 more
core   +2 more sources

ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma [PDF]

Oncotarget, 2019
Hepatic angiosarcoma (HAS) is a rare and highly lethal malignancy with few effective systemic treatments. Relatively little is known about the genetic abnormalities that drive this disease. As a result, there has been minimal progress towards applying targeted therapies to the treatment of HAS.
Marks, Eric I., Pamarthy, Sahithi, Dizon, Don, Birnbaum, Ari, Yakirevich, Evgeny, Safran, Howard, Carneiro, Benedito A.   +6 more
openaire   +2 more sources

Genetic analysis of the Replication Protein A large subunit family in Arabidopsis reveals unique and overlapping roles in DNA repair, meiosis and DNA replication [PDF]

, 2013
Replication Protein A (RPA) is a heterotrimeric protein complex that binds single-stranded DNA. In plants, multiple genes encode the three RPA subunits (RPA1, RPA2 and RPA3), including five RPA1-like genes in Arabidopsis.
Aklilu, Behailu B., Culligan, Kevin M., Soderquist, Ryan S.   +2 more
core   +5 more sources

Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing

Molecular Oncology, 2020
ROS1 gene rearrangements have been reported in diverse cancer types including non‐small‐cell lung cancer (NSCLC), and with a notably higher prevalence in lung adenocarcinoma.
Meiying Cui, Yuchen Han, Pan Li, Jianying Zhang, Qiuxiang Ou, Xiaoling Tong, Ruiying Zhao, Nan Dong, Xue Wu, Wencai Li, Guozhong Jiang   +10 more
doaj   +1 more source

Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer. [PDF]

N Engl J Med
The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion-positive non-small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI with preclinical activity against ROS1 fusion-positive
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC, TRIDENT-1 Investigators.   +33 more
europepmc   +6 more sources

A secondary RET mutation in the activation loop conferring resistance to vandetanib [PDF]

, 2018
Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. The resistant tumor acquired a secondary mutation resulting
A Drilon, AE Drilon, AT Shaw, B Cosci, B Hess, B Hess, B Pasche, CH Yun, CI Bayly, D Plenker, DR Camidge, G Bussi, G Manning, H Bando, H Fujitani, HJC Berendsen, I Plaza-Menacho, J Goto, J Wang, JB Brown, K Lindorff-Larsen, K Yoh, KL Meagher, L Sutto, LM Mulligan, M Araki, M Parrinello, MW Schmidt, P Emsley, PD Adams, PP Knowles, PP Knowles, T Darden, T Kohno, T Mizukami, WL Jorgensen, YL Choi, YM Koyama   +37 more
core   +5 more sources

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins [PDF]

Proceedings of the National Academy of Sciences, 2013
Significance ROS1 fusion kinases are critical oncogenes in several malignancies, suggesting that ROS1 inhibitors are likely to be effective molecularly targeted therapies in these patients. Although phase I/II clinical trials using the ALK/ROS1 inhibitor crizotinib to treat ROS1 fusion-harboring non–small-cell lung cancer ...
Monika A, Davare, Anna, Saborowski, Christopher A, Eide, Cristina, Tognon, Rebecca L, Smith, Johannes, Elferich, Anupriya, Agarwal, Jeffrey W, Tyner, Ujwal P, Shinde, Scott W, Lowe, Brian J, Druker   +10 more
openaire   +2 more sources

Importance of ROS1 fene fusions in non-small cell lung cancer

Cancer Drug Resistance, 2023
Targeted therapy has become one of the standards of care for advanced lung cancer. More than 10 genetic aberrations have been discovered that are actionable and several tyrosine kinase inhibitors (TKIs) have been approved to target each of them.
Muminovic, Meri, Carracedo Uribe, Carlos Rodrigo, Alvarez-Pinzon, Andres, Shan, Khine, Raez, Luis E.   +4 more
openaire   +2 more sources

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. [PDF]

PLoS ONE, 2013
The targeting of oncogenic 'driver' kinases with small molecule inhibitors has proven to be a highly effective therapeutic strategy in selected non-small cell lung cancer (NSCLC) patients.
Kurtis D Davies, Sakshi Mahale, David P Astling, Dara L Aisner, Anh T Le, Trista K Hinz, Aria Vaishnavi, Paul A Bunn, Lynn E Heasley, Aik-Choon Tan, D Ross Camidge, Marileila Varella-Garcia, Robert C Doebele   +12 more
doaj   +1 more source